如何优化心力衰竭患者的目标导向医疗疗法 (GDMT)。

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI:10.1007/s11886-024-02101-x

Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky

{"title":"如何优化心力衰竭患者的目标导向医疗疗法 (GDMT)。","authors":"Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky","doi":"10.1007/s11886-024-02101-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to <math><mo>≤</mo></math> 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"995-1003"},"PeriodicalIF":3.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379751/pdf/","citationCount":"0","resultStr":"{\"title\":\"How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.\",\"authors\":\"Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky\",\"doi\":\"10.1007/s11886-024-02101-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to <math><mo>≤</mo></math> 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.\",\"PeriodicalId\":10829,\"journal\":{\"name\":\"Current Cardiology Reports\",\"volume\":\" \",\"pages\":\"995-1003\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379751/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Cardiology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11886-024-02101-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02101-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

审查目的：心力衰竭是一种临床综合征，具有潜在心脏异常引起的症状和体征，以及实验室检查或其他客观发现的肺部或全身充血证据（Bozkurt 等，载于 Eur J Heart Fail 23:352-380, 2021）。射血分数降低型心衰（HFrEF），即射血分数降低至≤40的潜在心衰。本综述旨在简要介绍 2022 年 AHA/ACC/HFSA 指南中所述各种药物干预的机制和益处，重点关注 C 阶段：症状性心力衰竭 HFrEF，同时提供安全使用这些药物的基本指导：根据《2022 年指南》的建议使用各类药物可为患者带来显著的发病率和死亡率方面的益处。尽管针对 HFrEF 患者的治疗方法不断进步，但患者往往得不到充分治疗，因此需要开展更多研究，以帮助优化对这些复杂患者的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.

Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to $\leq$ 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.

Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.